CLOV Q3 Earnings Miss, Stock Falls on Raised Insurance BER View

Clover Health (CLOV) reported break-even adjusted Q3 EPS, missing estimates, despite revenues surging 50.1% year-over-year to $496.7 million, which beat expectations. However, the company's Insurance Benefit Expense Ratio (BER) rose significantly to 92.4% from 85.4% due to increased medical utilization and new member growth, prompting a lowered 2025 adjusted net income forecast from $50-$70 million to $15-$30 million and a raised BER projection. Following these mixed results and the reduced profitability outlook, CLOV shares fell 17.9% in after-hours trading.

Analysis

Clover Health (CLOV) reported a mixed third quarter 2025, with adjusted EPS breaking even, missing the Zacks Consensus Estimate of 2 cents, and a loss per share from continuing operations of 5 cents. Despite this, total revenues surged 50.1% year-over-year to $496.7 million, surpassing estimates by 4.5%, driven by a 48.5% increase in Insurance revenues due to 35% Medicare Advantage membership growth. However, the Insurance Benefit Expense Ratio (BER) significantly increased to 92.4% from 85.4%, primarily due to heavy new-member growth and elevated medical utilization.

The rising BER and associated cost pressures led CLOV to lower its 2025 adjusted net income guidance to $15-$30 million from the previous $50-$70 million, while raising its BER projection to 90-91%. This revised outlook, despite an upward adjustment in 2025 Insurance revenue estimates, triggered a 17.9% decline in CLOV shares during after-hours trading. The company's year-to-date stock performance of 11.7% also lags the industry's 26.8% growth and the S&P 500's 18.1%.

Management anticipates a path to profitability expansion in 2026, citing expected moderation of BER pressures as new cohorts mature under Clover Assistant management. Tailwinds include favorable payment dynamics from a 4-star year, CMS rate updates, and increased Part D subsidies. The Clover Assistant platform continues to demonstrate strong clinical quality, and its potential for external adoption presents a significant long-term growth opportunity.

Key Decisions for Investors

• Investors should closely monitor Clover Health's Benefit Expense Ratio (BER) trends and management's execution on cost moderation strategies as new member cohorts mature.
• Evaluate the trade-off between robust top-line growth and the revised, lower short-term income guidance, considering the company's stated path to profitability expansion in 2026.
• Assess the current valuation following the 17.9% after-hours stock decline, particularly in light of the long-term potential from the Clover Assistant platform's external adoption and anticipated tailwinds.